Breaking News

Almac Expands UK Commercial Capacity

October 3, 2012

Acquires new blistering technology

Almac has expanded its MHRA/FDA-approved UK commercial packaging facility with the acquisition of a Noack N 623 blister packaging line from Romaco. The line accommodates enhanced flexibility for larger blister sizes and multi unit blister formats, coupled with a requirement for non-permeability and enhanced environmental protection.
 
This cGMP-compliant technology can be configured to process both thermoform and coldform materials, with maximum blister sizes of 220mm x 155mm. The Noack N 623 has an automatic feeding system, filling inspection and ejection station and shorter set-up times. It can process more than 25,000 blisters per hour, including multi-product blisters.
 
“Blister size and dosage formats are becoming increasingly more complex. Additionally, product handling for innovative new molecules often requires enhanced environmental controls. This investment allows Almac, through its Pharma Services business unit, to offer this additional flexibility,” said Geoff Sloan vice president of manufacturing operations. “Through this acquisition, coupled with our immanent entry into the U.S. commercial packaging market, we continue to expand our capabilities and flexibility to meet our client’s needs.”

Related Contract Manufacturing:

Related Packaging:

blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision